Cinven pays £2.2 billion for Theramex, valuing women's health platform at 4x 2018 entry

Cinven agreed to acquire Theramex from Carlyle Group and PAI Partners for approximately £2.2 billion, marking the women's health pharmaceutical company's third private equity ownership change in seven years. The price represents roughly four times the valuation when Carlyle and PAI acquired the business in 2018, delivering a 300% gross markup to the sellers over a six-year hold.

Theramex manufactures and distributes hormone replacement therapies, contraceptives, and fertility treatments across Europe and emerging markets. The company operates as a specialty pharma platform with minimal in-house R&D, instead acquiring or licensing mature products with established reimbursement pathways. Revenue was not disclosed, but the £2.2 billion enterprise value suggests annual sales in the £400-500 million range at standard women's health pharma multiples of 4-5x sales. Carlyle and PAI Partners originally paid an estimated £550 million for the asset in 2018, inheriting a portfolio that included branded menopause and contraception franchises.

The valuation expansion reflects three structural dynamics. First, women's health has shifted from a pharma backwater to a venture and buyout priority, with female-focused therapeutics raising $3.2 billion in private capital in 2023 alone, according to PitchBook. Second, sponsor-to-sponsor continuation deals now account for 37% of European buyout exits by value in 2024, up from 19% five years ago, per Preqin. Theramex fits the profile: defensible cash flow, fragmented end markets, and a proven thesis that derisks underwriting for the next buyer. Third, Cinven enters with €12 billion of undeployed capital across its eighth flagship fund and healthcare-dedicated vehicles, making the firm a natural acquirer of assets too large for traditional strategic buyers but too mature for VC-style growth mandates.

The transaction structure matters more than the headline price. Carlyle and PAI Partners financed their 2018 acquisition with approximately £200 million of equity and £350 million of debt, according to contemporaneous filings. If Cinven assumes minimal rollover and finances similarly at today's rates — roughly 60% debt at 7-8% cost — the implied debt load is £1.3 billion, which pencils at 2.6-3.25x EBITDA if EBITDA margins run 15-20%. That leverage sits comfortably below the 4-5x seen in riskier consumer or industrials deals, signaling lenders view the asset as recession-resistant. Cinven will likely pursue the same playbook Carlyle and PAI executed: bolt-on acquisitions in fertility and peri-menopause categories, geographic expansion into the Middle East and Latin America, and margin expansion through manufacturing consolidation.

Operators and allocators should watch three catalysts over the next 12-18 months. First, whether Cinven announces a follow-on acquisition within six months, which would confirm platform strategy and validate the valuation multiple. Second, any movement in Theramex's debt pricing on secondary markets, where tightening spreads would indicate sponsor confidence in near-term EBITDA growth. Third, whether Carlyle and PAI deploy their exit proceeds into new women's health platforms, which would signal they view the sector as durably backable rather than cyclically frothy.

This is the third time Theramex has changed PE hands since 2017. That cadence is the tell. When the same sector trades cleanly between sponsors at escalating multiples, the assumption is no longer opportunistic arbitrage but permanent capital rotation. Women's health is no longer a niche.